Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
25 lessons
9mPeptidesIntermediate
Therapeutic Peptides in Gerontology: What Healthy Aging Research Actually Shows
Healthy aging is not a slogan. It is a measurable question about inflammation, tissue repair, metabolic control, and whether a peptide has human data behind it.
9mResearchAdvanced
GLP-1s and Muscle Health: What the Latest Meta-Analysis Means for Body Recomposition
GLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.
9mResearchAdvanced
Tesamorelin and Liver Fat: Why the TESA-LIVER Trial Matters
Tesamorelin has one of the cleanest human-data stories in the peptide space. The new liver fat trial matters because it asks whether that signal extends into fatty liver disease.
8mResearchAdvanced
Retatrutide and Food Noise: Why Appetite Control Changes Adherence
The scale is only part of the story. Retatrutide's biggest advantage may be how it quiets food noise and makes adherence easier to sustain.
8mResearchAdvanced
GLP-1 Muscle Preservation: How to Keep Lean Mass While Losing Fat in 2026
GLP-1s can drive impressive weight loss, but the real win is losing fat without giving up strength. This guide shows how to protect lean mass while appetite is down.
9mPeptidesIntermediate
MOTS-C and Mitochondrial Repair: Why This Peptide Keeps Showing Up in Recovery Research
MOTS-C sits at the intersection of mitochondrial signaling, glucose control, and recovery biology. Here is what the current research can actually support.
8mPeptidesIntermediate
GLP-1s and Biological Aging: What the New Semaglutide Study Shows
GLP-1 research is moving into healthspan and epigenetic aging. The new semaglutide signal is worth tracking, but it is not proof of age reversal.
8mPeptidesIntermediate
GLP-1s and Breast Cancer Risk: What the New Signal Means
GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
7mPeptidesIntermediate
CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026
GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.
7mResearchAdvanced
GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
8mResearchAdvanced
MOTS-c and Mitochondrial Metabolism: What the 2026 Human Trial Is Testing
MOTS-c is one of the most interesting mitochondrial peptides in 2026 because the question is finally shifting from mechanism to human outcomes.
7mPeptidesIntermediate
Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means
Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.
8mResearchAdvanced
Tesamorelin and Visceral Fat: What the 2026 Meta-Analysis Shows
Tesamorelin has one of the stronger human-data profiles in the peptide space. A 2026 meta-analysis helps clarify what it improves, what it does not, and how to track the signal honestly.
7mResearchAdvanced
GLP-1 Lean Mass Loss: What 2026 Data Shows
A new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.
8mResearchAdvanced
GLP-1 Nutrition Strategy: Protein, Muscle, and Labs
New 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.
7mResearchAdvanced
Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows
Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
7mResearchAdvanced
Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means
31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.
9mResearchAdvanced
GLP-1 Food Noise: Why It Comes Back After Stopping and What Actually Helps
Food noise — that constant mental chatter about food — often comes back after stopping GLP-1 peptides. Here's the science of why, and what actually helps: maintenance strategies, stacking options, and realistic expectations.
9mResearchAdvanced
GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
10mPeptidesIntermediate
MOTS-C Long-Term Use: Does Your Body Stop Responding?
MOTS-C activates AMPK and drives mitochondrial adaptation — but does daily use over months cause your body to stop responding? Here's what the research and user experience actually says about long-term MOTS-C protocols.
9mPeptidesIntermediate
Tesamorelin: The Science-Backed Growth Hormone Peptide for Fat Loss and Longevity
Tesamorelin is an FDA-approved GHRH analog with clinical trials proving 15–20% visceral fat reduction. Here's the full science, dosing guide, and what the latest research reveals about its longevity applications.
7mPeptidesIntermediate
MOTS-C Dosing Guide: Recommended Dose and How to Take It
MOTS-C is one of the most studied mitochondrial peptides for metabolic health and longevity. This guide covers dosing ranges, frequency, timing, stacking options, and what to track on protocol.
10mResearchAdvanced
Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows
TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.
10mPeptidesIntermediate
MOTS-C: The Peptide That Optimizes Mitochondrial Function
MOTS-C activates mitochondrial function and metabolic pathways linked to longevity and improved physical performance.
12mPeptidesIntermediate
GLP-1 Agonists for Metabolic Health: Clinical Evidence & Body Recomposition Strategy
GLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.
Also available at /blog for legacy links.